EAM
DGX icon

Eventide Asset Management’s Quest Diagnostics DGX Stock Holding History

Eventide Asset Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$280K Buy
1,316
+204
+18% +$40K ﹤0.01% 265
2026
Q1 		$219K Buy
+1,112
New +$216K ﹤0.01% 262

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Eventide Asset Management's DGX Position: Q2 2026 in Review

Eventide Asset Management increased its Quest Diagnostics (DGX) stake by 18% in Q2 2026, buying an estimated $40K and bringing the position to 1,316 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #265.

Eventide Asset Management first reported a position in DGX in Q1 2026 and has held it in 2 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Eventide Asset Management held 1,316 shares of Quest Diagnostics worth $280K as of Q2 2026.
  • Eventide Asset Management bought 204 Quest Diagnostics shares in Q2 2026, an estimated $40K.
  • Quest Diagnostics made up ﹤0.01% of Eventide Asset Management's portfolio in Q2 2026, its #265 holding.
  • Eventide Asset Management first reported a position in Quest Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.